Review



human arterial smcs (hasmcs)  (Lonza)


Bioz Verified Symbol Lonza is a verified supplier
Bioz Manufacturer Symbol Lonza manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 90

    Structured Review

    Lonza human arterial smcs (hasmcs)
    Human Arterial Smcs (Hasmcs), supplied by Lonza, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+arterial+smcs+%28hasmcs%29/10__1161_slash_atvbaha__123__319400-67-6-13?v=Lonza
    Average 90 stars, based on 1 article reviews
    human arterial smcs (hasmcs) - by Bioz Stars, 2026-08
    90/100 stars

    Images



    Similar Products

    90
    Lonza human arterial smcs (hasmcs)
    Human Arterial Smcs (Hasmcs), supplied by Lonza, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+arterial+smcs+%28hasmcs%29/10__1161_slash_atvbaha__123__319400-67-6-13?v=Lonza
    Average 90 stars, based on 1 article reviews
    human arterial smcs (hasmcs) - by Bioz Stars, 2026-08
    90/100 stars
      Buy from Supplier

    90
    Lonza human arterial smcs (hasmcs
    N-cadherin–targeting chimeric peptide inhibited migration of human smooth muscle cells <t>(SMCs),</t> but not endothelial cells (ECs), and did not impact viability. Scratch-wounded human aortic SMCs <t>(HASMCs;</t> A ) or human umbilical vein endothelial cells (HUVECs; C ) were treated with N-cadherin–targeting chimeric peptide or scrambled control peptide and imaged after 48 hours. The area of the wound gap was subtracted from and divided by the initial gap area to give a percentage of the wound that had closed. For viability measurements, HASMCs ( B ) or HUVECs ( D ) were treated with N-cadherin–targeting chimeric peptide or scrambled control peptide and allowed to proliferate for 24 hours. Metabolic activity was assessed by colorimetric change of water-soluble tetrazolium salt, measured as absorbance at 450 nm, with background at 610 nm subtracted. Apoptosis was measured in HUVECs by staining for cleaved caspase 3 (CC3) and counting positively stained cells ( E ). Permeability was measured in HUVECs grown on transwell membranes with 0.4-μm pores where the top chamber media replaced with 5 μM fluorescein isothiocyanate (FITC)–dextran and N-cadherin peptide or scrambled control. Media in the abluminal ( bottom ) chamber was sampled into a 96-well dish and luminescence at 530 nm read by plate reader. FITC-dextran concentration calculated against a standard curve ( F ). Data shown are means±SEM; n≥3 biological replicates. Statistical significance was determined by 2-way ANOVA with Tukey multiple comparisons ( A–D ) or Mann-Whitney U tests ( E and F ).
    Human Arterial Smcs (Hasmcs, supplied by Lonza, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+arterial+smcs+%28hasmcs%29/pmc10443629-28-6-13?v=Lonza
    Average 90 stars, based on 1 article reviews
    human arterial smcs (hasmcs - by Bioz Stars, 2026-08
    90/100 stars
      Buy from Supplier

    Image Search Results


    N-cadherin–targeting chimeric peptide inhibited migration of human smooth muscle cells (SMCs), but not endothelial cells (ECs), and did not impact viability. Scratch-wounded human aortic SMCs (HASMCs; A ) or human umbilical vein endothelial cells (HUVECs; C ) were treated with N-cadherin–targeting chimeric peptide or scrambled control peptide and imaged after 48 hours. The area of the wound gap was subtracted from and divided by the initial gap area to give a percentage of the wound that had closed. For viability measurements, HASMCs ( B ) or HUVECs ( D ) were treated with N-cadherin–targeting chimeric peptide or scrambled control peptide and allowed to proliferate for 24 hours. Metabolic activity was assessed by colorimetric change of water-soluble tetrazolium salt, measured as absorbance at 450 nm, with background at 610 nm subtracted. Apoptosis was measured in HUVECs by staining for cleaved caspase 3 (CC3) and counting positively stained cells ( E ). Permeability was measured in HUVECs grown on transwell membranes with 0.4-μm pores where the top chamber media replaced with 5 μM fluorescein isothiocyanate (FITC)–dextran and N-cadherin peptide or scrambled control. Media in the abluminal ( bottom ) chamber was sampled into a 96-well dish and luminescence at 530 nm read by plate reader. FITC-dextran concentration calculated against a standard curve ( F ). Data shown are means±SEM; n≥3 biological replicates. Statistical significance was determined by 2-way ANOVA with Tukey multiple comparisons ( A–D ) or Mann-Whitney U tests ( E and F ).

    Journal: Arteriosclerosis, Thrombosis, and Vascular Biology

    Article Title: Matrix-Binding, N-Cadherin–Targeting Chimeric Peptide Inhibits Intimal Thickening but Not Endothelial Repair in Balloon-Injured Carotid Arteries

    doi: 10.1161/ATVBAHA.123.319400

    Figure Lengend Snippet: N-cadherin–targeting chimeric peptide inhibited migration of human smooth muscle cells (SMCs), but not endothelial cells (ECs), and did not impact viability. Scratch-wounded human aortic SMCs (HASMCs; A ) or human umbilical vein endothelial cells (HUVECs; C ) were treated with N-cadherin–targeting chimeric peptide or scrambled control peptide and imaged after 48 hours. The area of the wound gap was subtracted from and divided by the initial gap area to give a percentage of the wound that had closed. For viability measurements, HASMCs ( B ) or HUVECs ( D ) were treated with N-cadherin–targeting chimeric peptide or scrambled control peptide and allowed to proliferate for 24 hours. Metabolic activity was assessed by colorimetric change of water-soluble tetrazolium salt, measured as absorbance at 450 nm, with background at 610 nm subtracted. Apoptosis was measured in HUVECs by staining for cleaved caspase 3 (CC3) and counting positively stained cells ( E ). Permeability was measured in HUVECs grown on transwell membranes with 0.4-μm pores where the top chamber media replaced with 5 μM fluorescein isothiocyanate (FITC)–dextran and N-cadherin peptide or scrambled control. Media in the abluminal ( bottom ) chamber was sampled into a 96-well dish and luminescence at 530 nm read by plate reader. FITC-dextran concentration calculated against a standard curve ( F ). Data shown are means±SEM; n≥3 biological replicates. Statistical significance was determined by 2-way ANOVA with Tukey multiple comparisons ( A–D ) or Mann-Whitney U tests ( E and F ).

    Article Snippet: Human umbilical vein ECs (HUVECs) and human arterial SMCs (HASMCs) were purchased from Lonza (Basel, Switzerland) and cultured in EGM-2 (endothelial growth medium-2; Lonza) or SmGm-2 (smooth muscle growth medium-2; Lonza) media supplemented with the included bullet kit according to the manufacturer’s instructions.

    Techniques: Migration, Activity Assay, Staining, Permeability, Concentration Assay, MANN-WHITNEY